About this event

  • Date and time Fri 14 Jan 2022 from 8:00am to 5:05pm
  • Location Royal Society of Medicine
  • Organised by Oncology, Medical Genetics

Join us to understand how critically important the genetic and epigenetic changes in cancer are for disease biology and novel treatments.

Learning objectives include:

  • The role of genetic and epigenetic changes in cancer biology with examples of how this has already impacted patient treatment and survival
  • Novel emerging technologies such as gene-editing and radiomics to understand how these may lead to new therapies and predictors of response, respectively
  • Gain an insight into the trials and tribulations of genetic testing from a consumer point of view

This meeting will be relevant to clinical and medical oncologists, geneticists, basic scientists interested in cancer biology and genetics (cancer researchers), radiologist, pathologists, pharmacists, cancer researchers and cancer nurses, medical students and trainees interested in cancer and genetics.

This event is available for on-demand viewing. The event recording will be available for registered delegates up to 60 days after the live broadcast via Zoom. The link will be sent 24 hours after the event takes place.

Join in the conversation online #RSMLive
Follow us on Twitter: @RoySocMed 

Tickets

Early Bird pricing available until 03 December 2021.

Member

RSM Fellow RSM Associate RSM Retired Fellow RSM Trainee RSM Student
£77.00 £46.00 £46.00 £46.00 £24.00

Non - Member

Consultant / GP AHP / Nurse / Midwife Non Healthcare Professional Trainee Student
£141.00 £84.00 £84.00 £84.00 £44.00

Key speakers

Professor Alan Ashworth

E. Dixon Heise Distinguished Professor in Oncology, University of California San Francisco, President, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, Senior Vice President for Cancer Services,  University of California San Francisco Health, Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, United States of America

Professor Clare Scott

Professor of Gynaecological Cancer, University of Melbourne, Joint Head, Clinical Translation Centre, Laboratory Head, Walter and Eliza Hall Institute of Medical Research, Medical Oncologist, Peter MacCallum Cancer Centre, Royal Melbourne and Royal Women's Hospitals, Australia

Professor Ian Tomlinson

Director, Cancer Research UK Edinburgh Centre, Charles and Ethel Barr Chair of Cancer Research

Agenda

View the programme

Registration, tea and coffee
Welcome and introduction

Session one: Genetics

Breast cancer genetics

Professor Alan Ashworth, E. Dixon Heise Distinguished Professor in Oncology, University of California San Francisco, President, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, Senior Vice President for Cancer Services,  University of California San Francisco Health, Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, United States of America

Ovarian cancer genetics

Professor Clare Scott, Professor of Gynaecological Cancer, University of Melbourne, Joint Head, Clinical Translation Centre, Laboratory Head, Walter and Eliza Hall Institute of Medical Research, Medical Oncologist, Peter MacCallum Cancer Centre, Royal Melbourne and Royal Women's Hospitals, Australia

Parp inhibitors in clinical practice

Dr Susana Banerjee, Consultant Medical Oncologist and Research Lead for the Gynaecology Unit, The Royal Marsden NHS Foundation Trust

Tea and coffee break

Session two: Epigenetics

Epigenetics in cancer

Professor Idriss Bennani-Baiti, President and Chief Executive Officer, Cancer Epigenetics Society, Austria

Neuroendocrine tumours - cracking the epigenetic code

Professor Chrissie Thirlwell, Mireille Gillings Professor of Cancer Genomics, University of Exeter Medical School, Exeter

Epigenetic treatment strategies for ovarian cancer

Professor Robert Brown, Senior Research Investigator. Imperial College London

Session three: Debate: Direct to consumer genetic testing for cancer

Mr Christian Holland, Oxford University Hospitals NHS Foundation Trust

Pro
Con
Vote
Lunch

Session four: Technological advances in cancer and genetics

Leveraging the microbiome for improved cancer outcomes

Dr James Kinross, Senior Lecturer in Surgery, Imperial College London

Radiomics

Professor Eric Aboagye, Professor of Cancer Pharmacology & Molecular Imaging, Imperial College London

CRISPR technology – Is it clinic ready?

Dr Claire Roddie, Consultant Haematologist, University College London Hospitals NHS Foundation Trust, Honorary Senior Lecturer in Haematology, University College London

Tea and coffee break

Session five: Targeted genetic treatment old and new

Epidermal growth factor receptor inhibitors

Professor Fiona Blackhall, Professor of Thoracic Oncology, Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust, Manchester

Gene therapy

Professor Malcolm Brenner, Center for Cell and Gene Therapy, Baylor College of Medicine, United States of America

Plenary session: Colorectal cancer genetics and new targets for treatment

Professor Ian Tomlinson, Director, Cancer Research UK Edinburgh Centre, Charles and Ethel Barr Chair of Cancer Research

Close of meeting

Location

Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom

Disclaimer: All views expressed in this webinar are of the speakers themselves and not of the RSM nor the speaker's organisations. 

Special rates for difficult times  

The RSM wishes to offer healthcare professionals continued learning opportunities during the coronavirus pandemic. The RSM’s weekly COVID-19 Series webinars remain free of charge, while there will be small charges to register for other online education. These fees will enable the RSM to continue its programme of activities and will apply during the course of the pandemic. 

Man searching computer

Join the RSM and get unlimited digital learning and e-resources access

The RSM has an extensive digital learning and online e-resources platform. As a member you'll enjoy unlimited digital learning any time you need and access to e-journals, e-books and 6 huge medical databases to support your clinical decision-making and research.

Our e-resources are updated continuously to ensure you receive the cutting edge knowledge you need. 

 

Become a member